Thu.May 02, 2024

article thumbnail

Moderna gears up for potential RSV vaccine launch this fall after better-than-expected first quarter

Fierce Pharma

With Moderna’s COVID-19 sales on the backfoot following the switch to an endemic vaccine market, the Massachusetts-based biopharma is busy laying the groundwork for its next potential mRNA shot in | Moderna currently expects initial approvals of its RSV vaccine to start rolling in during the first half of 2024, the company said Thursday. In turn, the company is eyeing a potential U.S. launch in the fall, which would capitalize on its established commercial efforts in the seasonal COVID-19 immuni

Biopharma 271
article thumbnail

Long-acting antibody demonstrates promising efficacy in infant RSV

European Pharmaceutical Review

Interim results of an ongoing study published in The Lancet have reported that Beyfortus (nirsevimab) reduced respiratory syncytial virus (RSV) hospitalisations by 82 percent in infants under six months, compared to infants who received no RSV intervention. Sanofi noted that as a long-acting antibody, Beyfortus has been shown to provide rapid protection, helping to prevent lower respiratory tract disease caused by RSV without the immune system needing activation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Facing pricing pressure from Lilly's Zepbound, Novo Nordisk scales Wegovy supply

Fierce Pharma

Novo Nordisk is facing fierce competition from Eli Lilly’s obesity rival Zepbound, which has shaken up U.S. pricing dynamics for the Danish company's popular GLP-1 drug. | Novo Nordisk is facing fierce competition from Eli Lilly’s obesity rival Zepbound, which has shaken up U.S. pricing dynamics for the Danish company's popular GLP-1 drug.

article thumbnail

Novartis Extends Its Reach in Radiopharmaceuticals With $1B Mariana Oncology Acquisition

MedCity News

Mariana Oncology brings Novartis a lead radiopharmaceutical program in development for small cell lung cancer. The deal is the latest in a string of big pharma M&A moves in the red-hot radiopharmaceuticals space. The post Novartis Extends Its Reach in Radiopharmaceuticals With $1B Mariana Oncology Acquisition appeared first on MedCity News.

Pharma 122
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

As Imbruvica bows out, AstraZeneca clinches early Calquence win in newly diagnosed MCL

Fierce Pharma

As AbbVie and Johnson & Johnson’s Imbruvica retreated, AstraZeneca’s Calquence has become the first BTK inhibitor to claim a unique win in previously untreated mantle cell lymphoma (MCL). | AstraZeneca is touting a earlier-than-expected positive readout for Calquence in first-line mantle cell lymphoma. But a big question remains whether it can immediately file with the FDA, especially given the precedent of Imbruvica.

FDA 258
article thumbnail

MHRA publishes strategy on AI regulation

European Pharmaceutical Review

The Medicines and Healthcare products Regulatory Agency (MHRA) has published a policy paper on its strategic approach to artificial intelligence (AI). It summarises the MHRA’s view on the UK government’s white paper on AI regulation published in 2023. Following publication of this white paper, the government requested that the MHRA outline the steps the agency is working on in relation to its expectations.

Safety 115

More Trending

article thumbnail

The top pharmaceutical companies by R&D expenditure

Pharmaceutical Technology

From Merck & Co to Sanofi, Pharmaceutical Technology lists the leading pharmaceutical companies spending the most on R&D in 2023.

article thumbnail

Regeneron reveals potential delay for Dupixent in COPD, stagnant sales for Eylea

Fierce Pharma

Sanofi and Regeneron’s highly anticipated approval of Dupixent to treat chronic obstructive pulmonary disease (COPD) could be delayed, Regeneron CEO Len Schleifer said on Thursday. | Sanofi and Regeneron’s highly anticipated approval of Dupixent to treat COPD could be delayed, as the FDA has requested additional efficacy data from two trials. The regulatory hurdle comes as Eylea showed stagnant sales, even though its new high-dose formula is seeing increased uptake.

Sales 190
article thumbnail

Kaiser Permanente Is Deploying Innovaccer’s Value-Based Care AI Across Washington

MedCity News

Kaiser Permanente is deploying Innovaccer’s healthcare AI platform and population health management tools to support better value-based care — starting with its Washington market and potentially expanding to new markets in the future. The post Kaiser Permanente Is Deploying Innovaccer’s Value-Based Care AI Across Washington appeared first on MedCity News.

article thumbnail

Established Brands: Under Pressure to do More with Less? Explore Options to Thrive

Fierce Pharma

Kirk Harmon, Vice President and General Manager, Contract Sales Organization, IQVIA Jave Castillo, Vice President, CSO Solutions, IQVIA | Learn three ways CSO solutions can help your established brands sustain revenue until your new products begin to become profitable.

Sales 144
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

What is the future of biologic medicines?

European Pharmaceutical Review

Recent developments in the biologic therapies sector include the authorisation of Pyzchiva ® (biosimilar ustekinumab) by the European Commission, and promising 12-month data for Roche’s subcutaneous injection of OCREVUS ® (ocrelizumab) for relapsing or primary progressive multiple sclerosis. The biologics market is expected to continue its fast growth despite the slowdown in funding observed in the past year.

Medicine 105
article thumbnail

CCC Wins Five Top Workplaces Culture Excellence Awards

Copyright Clearance Center

May 2, 2024 – Danvers, Mass. – CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, announced today that it has earned five 2023 Top Workplaces Culture Excellence Awards from Energage LLC for Compensation & Benefits; Leadership; Work-Life Flexibility; Innovation; and Purpose & Values for the second consecutive year.

article thumbnail

How ACOs Can Harness AI’s Transformative Potential

MedCity News

Strategies for building the datasets needed for ACOs to take advantage of artificial intelligence, manage costs and improve outcomes for all The post How ACOs Can Harness AI’s Transformative Potential appeared first on MedCity News.

article thumbnail

$4M+ gene therapies? How payers can adapt to a new reality of pricey ‘cures’

PharmaVoice

Pricey gene therapies promise great benefit to patients but pose a threat to the payer landscape — ICER and a Tufts think tank are offering potential solutions.

article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

The Rising Stakes of Healthcare Data Privacy in 2024: The Need for Practical Guidance

MedCity News

Where we’ve been, where we’re going, and how healthcare organizations can protect themselves from privacy risks caused by the Meta pixel and other third-party trackers The post The Rising Stakes of Healthcare Data Privacy in 2024: The Need for Practical Guidance appeared first on MedCity News.

article thumbnail

RNA glioblastoma vaccine shows promise in first human trial

pharmaphorum

A personalised vaccine for the aggressive brain cancer glioblastoma developed has shown encouraging signs of efficacy in its first human trial.

108
108
article thumbnail

How Companies Can Improve Their Learning and Development Strategy and Why it is Essential in the Life Sciences Space

MedCity News

Some specific topics that should be prioritized at all levels The post How Companies Can Improve Their Learning and Development Strategy and Why it is Essential in the Life Sciences Space appeared first on MedCity News.

article thumbnail

Mobile app guides patients through surgical recovery

pharmaphorum

Hospital staff in the UK have developed and piloted an app that can help patients monitor their progress to recovery after surgeries.

Patients 109
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Xyphos and Poseida to develop allogeneic cell therapies for cancer

Pharmaceutical Technology

Xyphos Biosciences and Poseida Therapeutics have signed a deal to develop new allogeneic cell therapies for treating cancer.

96
article thumbnail

Astellas expands Poseida alliance on solid tumour CAR-Ts

pharmaphorum

Astellas turns to Poseida again to expand its CAR-T pipeline, adding two projects in solid tumours in a deal worth up to $600 million

104
104
article thumbnail

Novo Nordisk aims for market domination, boasts $1.5bn obesity sales in Q1

Pharmaceutical Technology

Novo Nordisk noted a 22% boost in sales owing to increased sales of GLP-1 agonists and other obesity products.

Sales 98
article thumbnail

Wegovy sales double, as starting restrictions start to lift

pharmaphorum

Sales of Novo Nordisk's obesity drug Wegovy double in Q1, as restrictions on starting doses start to lift in the US.

Sales 107
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Nova’s Xromi approved in UK and EU for vaso-occlusive complications of SCD

PharmaTimes

The inherited disorder is caused by genetic mutations that affects haemoglobin production

article thumbnail

Novartis digs deeper in radiopharma with $1.75bn Mariana buy

pharmaphorum

Novartis has struck another deal in radiopharmaceuticals, agreeing to pay $1bn upfront for radioligand therapy developer Mariana Oncology.

91
article thumbnail

Study reveals vitamin D-altered mouse gut bacteria provides better cancer immunity

PharmaTimes

Bacteroides fragilis in the gut improves immunity and immunotherapy treatment responses

94
article thumbnail

CDER Releases Office of New Drugs 2023 Annual Report

PharmaTech

The report covers the major achievements of the office during 2023, including notable drug approvals, publications, guidances, workshops, webinars, and meetings.

64
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Pharma Pulse 5/2/24: The Impact of IRA on Drug Prices and Patient Access, Early Communication Crucial for Successful Drug Launch & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 104
article thumbnail

Emerging Therapies and GMPs

PharmaTech

Guidance documents and interaction with FDA can help manufacturers stay in GMP compliance, says Siegfried Schmitt, VP Technical, at Parexel.

article thumbnail

Improving Patient Outcomes with Immersive Learning

Infuse Medical

In the healthcare Operations field, achieving the best possible patient outcomes is paramount. This means ensuring patients not only understand their diagnosis but are also empowered to participate actively in their treatment plan. Immersive learning, a cutting-edge educational approach, offers a unique opportunity to enhance patient education and understanding.

article thumbnail

Meeting Upstream Bioprocessing Challenges with Innovative Engineering Design (INTERPHEX 2024)

PharmaTech

Global product manager at Cytiva, Eric Corti, discusses the challenges with designing a new single-use mixing system that ensures leak-free fluid handling operations at INTERPHEX 2024.

article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A